sacituzumab govitecan + cisplatin + zimberelimab

This is a **combination regimen** consisting of sacituzumab govitecan (an antibody-drug conjugate targeting Trop-2), cisplatin (a platinum-based chemotherapeutic agent), and zimberelimab (a monoclonal antibody checkpoint inhibitor targeting PD-1). Sacituzumab govitecan delivers the SN-38 cytotoxic payload specifically to tumor cells expressing Trop-2, leading to cell death. Cisplatin induces DNA crosslinking and apoptosis in tumor cells. Zimberelimab blocks the PD-1 receptor on T cells, enhancing anti-tumor immune responses. This specific combination is being investigated in clinical trials for solid tumors, particularly **platinum-sensitive recurrent ovarian and endometrial cancer**, and is also being studied in urothelial carcinoma settings.

Brand names

TRODELVY (for sacituzumab govitecan)

Other names

SG (for sacituzumab govitecan)